Resources from the same session
Rare cancers vs rare subgroups, precision vs personalized medicine
Presenter: Paolo G. Casali
Session: Methodology (tumour agnostic)
Resources:
Slides
Webcast
The opportunities of agnostic drug development
Presenter: Sandra Strauss
Session: Methodology (tumour agnostic)
Resources:
Slides
Webcast
The ESMO Tumour-Agnostic Classifier as part of tumour-agnostic drug development
Presenter: Christoph Benedikt Westphalen
Session: Methodology (tumour agnostic)
Resources:
Slides
Webcast
Q&A and discussion
Session: Methodology (tumour agnostic)
Resources:
Webcast